

News Release

Biofrontera AG appoints Thomas Schaffer as Chief Financial Officer

Leverkusen, Germany, 03 June 2013 – Following the successful European approval of its first prescription drug and market introduction in several European markets, Biofrontera AG (DSE: B8F) announced today the appointment of Thomas Schaffer as Chief Financial Officer of the Company, effective immediately. Within the company, Mr. Schaffer will be responsible for Finance and Administration, Controlling and Investor Relations. In this position he succeeds Werner Pehlemann who will stay in the company for another month to promote Mr. Schaffer's integration and, by mutual agreement, leave on June 30th to pursue new entrepreneurial challenges. The change in the CFO position is related to the Company's international growth strategy.

Mr. Schaffer started his career in various functions in Finance and Controlling at Siemens Semiconductor, where he reached the position of Vice President and CFO of the Security & Chipcard ICs. After 4 years as Managing Director and CFO of Infineon Ventures GmbH, he continued as Vice President and CFO of the Specialty DRAM Division of Qimonda AG and became Managing Director of Qimonda Solar GmbH. CFO positions at Heptagon Oy, Finland/Switzerland, and Ubidyne Inc., Delaware, USA, completed his strong international experience. Mr. Schaffer played pivotal roles in reaching major corporate milestones for the companies he worked for, including capital raises, debt financings, corporate restructurings, M&A, and IPOs.

Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG, stated: "This further development of the team is a consequence of our international growth strategy. I am delighted to welcome Thomas Schaffer as new member of Biofrontera's Management Board. With his extensive experience in building successful companies and his impressive track record in business and corporate development, Thomas brings an excellent combination of technology business experience and financial background to our team to further build on our leadership position as a specialty pharma company in dermatology. He brings all the skills and experience required to move the

For further information please contact:

Anke zur Mühlen
Corporate Communication

+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen@biofrontera.com

Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

News Release

Company to the next level of success. Werner Pehlemann has played a hugely important role in building up this company. During his eight-year tenure at Biofrontera, he was crucial to the continued financing of Biofrontera as a research-based drug development company, thereby enabling its transformation to a young, dermatology-focused pharmaceutical company. Today Biofrontera has a strong financial position and an excellent basis for future success in its international growth strategy. I would like to thank Werner for his effective and very successful work on the board of the Company and his continued friendship. Along with all Biofrontera employees and the Supervisory Board, I wish him ongoing success for his future endeavors."

"I look forward to joining this exciting company in a challenging market environment. With an approved prescription drug and an unusually strong research base Biofrontera has the unique opportunity to become a successful player in dermatology. It is my goal to advance Biofrontera's vision and generate significant shareholder value in the years to come", commented Thomas Schaffer, now Chief Financial Officer of Biofrontera.

Werner Pehlemann added: "Biofrontera is at the beginning of an exciting phase of growth and development. We have achieved our internal milestones in forming Biofrontera into a specialty pharma company, and it has a first-class management team to take it forward. I am delighted that I had the opportunity to contribute to forming this company. I will follow Biofrontera as a shareholder and wish it continued success."

Biofrontera AG

Biofrontera aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection.

Biofrontera AG is listed on the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN number DE0006046113.

www.biofrontera.com

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking

News Release

statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.